Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Other Working Capital Changes: 2019-2025

Historic Other Working Capital Changes for Fulcrum Therapeutics (FULC) over the last 7 years, with Sep 2025 value amounting to -$44,000.

  • Fulcrum Therapeutics' Other Working Capital Changes rose 93.42% to -$44,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 million, marking a year-over-year decrease of 528.90%. This contributed to the annual value of -$2.0 million for FY2024, which is 286.66% down from last year.
  • As of Q3 2025, Fulcrum Therapeutics' Other Working Capital Changes stood at -$44,000, which was down 115.28% from $288,000 recorded in Q2 2025.
  • In the past 5 years, Fulcrum Therapeutics' Other Working Capital Changes registered a high of $1.7 million during Q4 2023, and its lowest value of -$4.3 million during Q1 2021.
  • Moreover, its 3-year median value for Other Working Capital Changes was -$179,000 (2023), whereas its average is -$228,818.
  • In the last 5 years, Fulcrum Therapeutics' Other Working Capital Changes crashed by 635.41% in 2021 and then surged by 467.47% in 2023.
  • Over the past 5 years, Fulcrum Therapeutics' Other Working Capital Changes (Quarterly) stood at -$1.4 million in 2021, then soared by 67.96% to -$455,000 in 2022, then surged by 467.47% to $1.7 million in 2023, then plummeted by 103.95% to -$66,000 in 2024, then skyrocketed by 93.42% to -$44,000 in 2025.
  • Its last three reported values are -$44,000 in Q3 2025, $288,000 for Q2 2025, and -$1.8 million during Q1 2025.